- Founded
- 1992
- Employees
- 5
- Total Funding
- $40M
Founded by Kevin Ryan in 1992.
About Transcend Therapeutics
Founded in 2021, Transcend Therapeutics is a late-clinical-stage neuroscience company developing rapid-acting treatments for neuropsychiatric diseases. Our lead asset TSND-201, a rapid-acting neuroplastogen, is the first and only product to demonstrate rapid, robust, and durable therapeutic effects in PTSD. TSND-201 was granted Breakthrough Therapy designation by the FDA based on Phase 2 results, and we have aligned on a Phase 3 program for TSND-201 in PTSD. Transcend is backed by leading life sciences investors and driven by a mission to create treatments for the millions of people for whom current psychiatric medicines have not worked.
Leadership at Transcend Therapeutics
The team at the top of the org chart.
Blake Mandell
Co-Founder & CEO
10 reports
Benjamin Kelmendi
Co-Founder & Chief Scientific Advisor
Martin Stogniew
Chief Development Officer
7 reports
Megan Kelly
Sr. Director Of Finance & Operations
Board
Kevin Ryan
Co-Founder & Chairman
Brenton Fargnoli
Board Member
Craig Nerenberg
Board Member
Lee Schalop
Advisor
Open Jobs at Transcend Therapeutics (5)
Similar companies hiring
Top employers in Health Care